chr3:12287368:> Detail (hg38)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr3:12,328,867-12,475,855 |
hg38 | chr3:12,287,368-12,434,356 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.004 | squamous cell carcinoma | NA | BeFree,LHGDN | Detail | |
0.080 | Cardiomyopathy, Alcoholic | NA | RGD | Detail | |
<0.001 | Cardiomyopathy, Dilated | NA | BeFree | Detail | |
<0.001 | hypertrophic cardiomyopathy | NA | BeFree | Detail | |
0.021 | Cardiovascular Diseases | PPARγ genetic variation has been associated with metabolic and cardiovascular di... | BeFree,GAD,LHGDN | 24841086 | Detail |
0.003 | Carotid Artery Diseases | NA | LHGDN | Detail | |
0.002 | cellulitis | NA | GAD | Detail | |
<0.001 | CNS disorder | NA | BeFree | Detail | |
<0.001 | cerebral infarction | NA | BeFree | Detail | |
0.002 | brain ischemia | NA | GAD | Detail | |
0.080 | Transient ischemic attack | NA | RGD | Detail | |
0.001 | Malignant tumor of cervix | The PPARγ is differentially expressed in cervical cancer cells with maximum expr... | BeFree | 24642720 | Detail |
0.002 | Chest Pain | NA | GAD | Detail | |
<0.001 | bile duct adenoma | NA | BeFree | Detail | |
0.003 | cholangitis | NA | BeFree,LHGDN | Detail | |
<0.001 | Primary biliary cirrhosis | NA | BeFree | Detail | |
0.003 | cholelithiasis | NA | BeFree,GAD | Detail | |
<0.001 | cholestasis | NA | BeFree | Detail | |
0.003 | chondrosarcoma | NA | BeFree,LHGDN | Detail | |
0.002 | chorioamnionitis | NA | GAD | Detail | |
0.003 | choriocarcinoma | NA | BeFree,LHGDN | Detail | |
0.002 | colitis | Altogether these data demonstrate that PAK1 overexpression and activation in inf... | BeFree | 26036343 | Detail |
0.148 | Colonic Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | Colonic Polyps | NA | BeFree | Detail | |
0.011 | colorectal carcinoma | The combination of resveratrol with a PPARγ agonist could be a promising pharmac... | BeFree | 24975132 | Detail |
0.011 | colorectal carcinoma | Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxalipla... | BeFree | 25075794 | Detail |
0.140 | Colorectal Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | cystic fibrosis | NA | BeFree | Detail | |
0.002 | Deafness | NA | GAD | Detail | |
<0.001 | Dehydration | NA | BeFree | Detail | |
<0.001 | Presenile dementia | NA | BeFree | Detail | |
<0.001 | Demyelinating Diseases | NA | BeFree | Detail | |
0.002 | Dental Plaque | NA | GAD | Detail | |
0.002 | Mental Depression | NA | GAD | Detail | |
0.003 | Dermatitis, Atopic | NA | BeFree,LHGDN | Detail | |
0.200 | Diabetes Mellitus, Experimental | NA | CTD_human,RGD | Detail | |
0.013 | Diabetes Mellitus, Insulin-Dependent | NA | BeFree,GAD | Detail | |
0.120 | lipoatrophic diabetes mellitus | NA | BeFree,ORPHANET | Detail | |
0.005 | Diabetic Angiopathies | NA | GAD | Detail | |
0.102 | Diabetic Nephropathy | NA | BeFree,GAD,LHGDN,RGD | Detail | |
0.002 | Diabetic Neuropathies | NA | GAD | Detail | |
0.008 | diabetic retinopathy | The gene polymorphisms of UCP1 but not PPAR γ and TCF7L2 are associated with dia... | BeFree,GAD,LHGDN | 25274455 | Detail |
<0.001 | Digestive System Disorders | NA | BeFree | Detail | |
0.002 | Dyspepsia | NA | GAD | Detail | |
<0.001 | Eczema | NA | BeFree | Detail | |
0.005 | Edema | NA | GAD | Detail | |
<0.001 | encephalitis | NA | BeFree | Detail | |
0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
0.007 | Endometrial Neoplasms | NA | GAD,LHGDN | Detail | |
0.011 | endometriosis | NA | BeFree,GAD,LHGDN | Detail | |
0.006 | Esophageal Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Exophthalmos | NA | BeFree | Detail | |
0.094 | Fatty Liver | NA | BeFree,GAD,LHGDN,RGD | Detail | |
0.080 | Fetal Growth Retardation | NA | RGD | Detail | |
0.002 | Fetal Membranes, Premature Rupture | NA | GAD | Detail | |
0.080 | Fibrosis | NA | RGD | Detail | |
0.003 | gastritis | NA | BeFree,GAD | Detail | |
0.002 | generalized atherosclerosis | NA | GAD | Detail | |
0.003 | glioblastoma | NA | BeFree,LHGDN | Detail | |
0.121 | Glioma | Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have a role of ant... | BeFree,CTD_human | 26003726 | Detail |
0.120 | glomerulonephritis | NA | CTD_human | Detail | |
0.003 | IgA glomerulonephritis | NA | BeFree,GAD | Detail | |
<0.001 | chronic granulomatous disease | NA | BeFree | Detail | |
0.003 | Graves Disease | NA | BeFree,GAD | Detail | |
0.002 | Growth Disorders | NA | GAD | Detail | |
0.002 | Hearing Loss, Partial | NA | GAD | Detail | |
0.002 | Heart Diseases | NA | GAD | Detail | |
0.006 | Heart failure | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | congestive heart failure | NA | BeFree | Detail | |
0.002 | hepatitis B | MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and ... | BeFree | 25595716 | Detail |
0.002 | Hirsutism | NA | GAD | Detail | |
0.007 | HIV Infections | NA | BeFree,GAD | Detail | |
0.002 | Hodgkin Disease | NA | GAD | Detail | |
<0.001 | Hunger | NA | BeFree | Detail | |
<0.001 | Huntington disease | NA | BeFree | Detail | |
0.003 | Hypercholesterolemia | NA | BeFree,GAD | Detail | |
0.009 | hyperglycemia | The sEng, sFlt-1, and interleukin-6 were up-regulated, whereas the VEGF and PlGF... | BeFree,GAD,LHGDN | 24793974 | Detail |
0.010 | hyperinsulinism | NA | BeFree,GAD,LHGDN | Detail | |
0.007 | Hyperlipidemia | NA | BeFree,GAD,LHGDN | Detail | |
0.009 | Hyperlipidemia, Familial Combined | NA | BeFree,GAD,LHGDN | Detail | |
0.258 | Hypertensive disease | NA | BeFree,CTD_human,GAD,LHGDN,RGD | Detail | |
0.010 | pulmonary hypertension | NA | BeFree,LHGDN | Detail | |
<0.001 | hyperthyroidism | NA | BeFree | Detail | |
0.005 | Hypertriglyceridemia | NA | GAD | Detail | |
<0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
0.224 | Inflammation | NA | CTD_human,GAD,LHGDN,RGD | Detail | |
0.006 | Inflammatory Bowel Diseases | Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, ... | BeFree,GAD | 24971461 | Detail |
0.006 | Inflammatory Bowel Diseases | Modulation of peroxisome proliferator-activated receptor gamma (PPAR γ) by conju... | BeFree,GAD | 25634802 | Detail |
<0.001 | influenza | NA | BeFree | Detail | |
0.200 | Insulin resistance | NA | CTD_human,GAD | Detail | |
0.123 | ischemia | Nitroalkene derivatives of oleic acid (OA-NO2) serve as high-affinity ligand for... | BeFree,CTD_human,LHGDN | 25766531 | Detail |
<0.001 | Keloid | NA | BeFree | Detail | |
0.004 | Kidney Diseases | NA | BeFree,GAD | Detail | |
<0.001 | Kidney Failure, Acute | NA | BeFree | Detail | |
0.005 | Kidney Failure, Chronic | Sequence variants of peroxisome proliferator-activated receptor-gamma gene and t... | BeFree,GAD | 25784779 | Detail |
0.003 | Kidney Neoplasm | NA | BeFree,GAD | Detail | |
0.002 | Premature Obstetric Labor | NA | GAD | Detail | |
0.003 | Fibroid Tumor | NA | BeFree,GAD | Detail | |
0.004 | leukemia | NA | BeFree,LHGDN | Detail | |
<0.001 | Leukemia, Myelocytic, Acute | NA | BeFree | Detail | |
0.001 | Myeloid Leukemia, Chronic | The phenotype and presence of two mutations suggests that biallelic mutations at... | BeFree | 24980513 | Detail |
0.001 | Myeloid Leukemia, Chronic | Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. | BeFree | 26331539 | Detail |
<0.001 | acute promyelocytic leukemia | NA | BeFree | Detail | |
<0.001 | Leukoencephalopathy, Progressive Multifocal | NA | BeFree | Detail | |
<0.001 | Lichen planus follicularis | NA | BeFree | Detail | |
0.002 | Lipid Metabolism, Inborn Errors | NA | GAD | Detail | |
0.120 | Lipoidosis | NA | CTD_human | Detail | |
<0.001 | lipoma | NA | BeFree | Detail | |
0.004 | liposarcoma | NA | BeFree,LHGDN | Detail | |
0.003 | liver cirrhosis | NA | BeFree,GAD | Detail | |
0.003 | Biliary cirrhosis | NA | LHGDN | Detail | |
0.080 | Liver Cirrhosis, Experimental | NA | RGD | Detail | |
0.005 | Liver diseases | NA | BeFree,GAD,LHGDN | Detail | |
0.122 | Liver neoplasms | Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepa... | BeFree,CTD_human | 25592041 | Detail |
<0.001 | Lung diseases | NA | BeFree | Detail | |
0.006 | Chronic Obstructive Airway Disease | NA | BeFree,GAD | Detail | |
0.015 | Lung Neoplasms | NA | BeFree,LHGDN | Detail | |
0.083 | Lupus Erythematosus, Systemic | NA | BeFree,GAD,MGD | Detail | |
0.003 | lymphoma | NA | BeFree,LHGDN | Detail | |
0.002 | Lymphoma, Non-Hodgkin | NA | GAD | Detail | |
<0.001 | malaria | NA | BeFree | Detail | |
<0.001 | Marfan syndrome | NA | BeFree | Detail | |
<0.001 | medulloblastoma | Similarly E2F transcription factors and PPARγ function in both progenitors and m... | BeFree | 24569090 | Detail |
0.129 | melanoma | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | premature menopause | NA | BeFree | Detail | |
<0.001 | Mesothelioma | NA | BeFree | Detail | |
0.126 | Metabolic Diseases | Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-activated tr... | BeFree,CTD_human,LHGDN | 25931782 | Detail |
0.006 | multiple myeloma | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | multiple sclerosis | In this study, we explored the distribution and role of the mitochondrial antiox... | BeFree,GAD | 25492529 | Detail |
<0.001 | muscular atrophy | NA | BeFree | Detail | |
<0.001 | myopathy | NA | BeFree | Detail | |
0.032 | myocardial infarction | NA | BeFree,GAD,LHGDN | Detail | |
0.008 | Neoplasm Metastasis | NA | BeFree,LHGDN | Detail | |
0.120 | Nerve Degeneration | NA | CTD_human | Detail | |
<0.001 | nervous system disorder | NA | BeFree | Detail | |
<0.001 | Nesidioblastosis | NA | BeFree | Detail | |
0.002 | neuroblastoma | NA | BeFree | Detail | |
<0.001 | Nevus | NA | BeFree | Detail | |
<0.001 | Melanocytic nevus | NA | BeFree | Detail | |
0.002 | orbit (eye disorders) | NA | GAD | Detail | |
0.122 | Degenerative polyarthritis | Association of PPARγ gene polymorphisms with osteoarthritis in a southeast Chine... | BeFree,CTD_human | 25572230 | Detail |
0.003 | Bone necrosis | NA | LHGDN | Detail | |
0.008 | osteoporosis | NA | BeFree,GAD | Detail | |
0.002 | Osteoporosis, Postmenopausal | NA | GAD | Detail | |
0.001 | osteosarcoma | Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ p... | BeFree | 25586304 | Detail |
0.002 | ovarian carcinoma | PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-12... | BeFree | 25944662 | Detail |
0.004 | Ovarian Diseases | NA | BeFree | Detail | |
0.080 | Pain | NA | RGD | Detail | |
0.131 | Pancreatic Neoplasm | NA | CTD_human,GAD,LHGDN | Detail | |
0.080 | pancreatitis | NA | BeFree,RGD | Detail | |
<0.001 | papilloma | NA | BeFree | Detail | |
<0.001 | Parkinson disease | Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a key regu... | BeFree | 25363075 | Detail |
0.005 | Peptic Ulcer | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | periodontitis | NA | BeFree,GAD | Detail | |
<0.001 | peritonitis | NA | BeFree | Detail | |
<0.001 | pituitary adenoma | NA | BeFree | Detail | |
<0.001 | Pituitary Diseases | NA | BeFree | Detail | |
0.004 | Pituitary Neoplasms | NA | BeFree,LHGDN | Detail | |
<0.001 | placental insufficiency | NA | BeFree | Detail | |
<0.001 | pneumonia | NA | BeFree | Detail | |
0.062 | polycystic ovary syndrome | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Adenomatous Polyposis Coli | NA | BeFree | Detail | |
<0.001 | polyps | NA | BeFree | Detail | |
0.005 | pre-eclampsia | NA | GAD | Detail | |
0.003 | Pregnancy Complications | NA | BeFree,GAD | Detail | |
0.002 | Prenatal Exposure Delayed Effects | NA | GAD | Detail | |
<0.001 | prolactinoma | NA | BeFree | Detail | |
0.011 | Prostatic Neoplasms | NA | BeFree,LHGDN | Detail | |
0.123 | psoriasis | NA | BeFree,CTD_human,LHGDN | Detail | |
0.002 | Delayed puberty | NA | GAD | Detail | |
0.002 | Precocious Puberty | NA | GAD | Detail | |
0.001 | pulmonary alveolar proteinosis | NA | BeFree | Detail | |
<0.001 | pulmonary emphysema | NA | BeFree | Detail | |
0.003 | pulmonary fibrosis | NA | LHGDN | Detail | |
0.005 | Rectal Neoplasms | NA | GAD,LHGDN | Detail | |
<0.001 | kidney failure | Further mechanistic study is needed to elucidate the role of PPAR-γ among ESRD p... | BeFree | 25784779 | Detail |
0.123 | Reperfusion Injury | NA | CTD_human,LHGDN | Detail | |
<0.001 | Respiratory Syncytial Virus Infections | NA | BeFree | Detail | |
<0.001 | retinal degeneration | NA | BeFree | Detail | |
<0.001 | retinoblastoma | NA | BeFree | Detail | |
0.003 | Salivary Gland Neoplasms | NA | BeFree,LHGDN | Detail | |
0.009 | sarcoidosis | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Sarcoidosis, Pulmonary | NA | BeFree | Detail | |
0.005 | schizophrenia | NA | BeFree,GAD | Detail | |
0.393 | Diabetes Mellitus, Non-Insulin-Dependent | We have genotyped three single nucleotide polymorphisms associated with type 2 d... | BeFree | 14988278 | Detail |
0.393 | Diabetes Mellitus, Non-Insulin-Dependent | In contrast, the well-documented associations of peroxisome proliferator-activat... | BeFree | 15561965 | Detail |
<0.001 | systemic scleroderma | A genome-wide association study follow-up suggests a possible role for PPARG in ... | BeFree | 24401602 | Detail |
<0.001 | systemic scleroderma | A candidate gene study reveals association between a variant of the Peroxisome P... | BeFree | 25986483 | Detail |
<0.001 | Septicemia | Activation of the peroxisome proliferator-activated receptor γ counteracts sepsi... | BeFree | 25559266 | Detail |
0.003 | Dermatologic disorders | NA | BeFree,GAD | Detail | |
0.002 | Starvation | NA | GAD | Detail | |
0.135 | Stomach Neoplasms | NA | CTD_human,GAD,LHGDN | Detail | |
0.014 | Cerebrovascular accident | PPARγ was not statistically significantly associated with stroke. | BeFree,GAD,LHGDN | 25659766 | Detail |
0.139 | Thyroid Neoplasm | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | Thyroid Nodule | PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinom... | BeFree | 24798894 | Detail |
0.002 | Tobacco use disorder | NA | GAD | Detail | |
<0.001 | Chagas disease | NA | BeFree | Detail | |
<0.001 | Attention Deficit Disorder | NA | BeFree | Detail | |
<0.001 | Uterine Fibroids | NA | BeFree | Detail | |
0.002 | Uterine Neoplasms | NA | GAD | Detail | |
0.003 | Vascular Diseases | NA | BeFree,LHGDN | Detail | |
0.014 | Weight Gain | NA | GAD | Detail | |
<0.001 | Werner syndrome | NA | BeFree | Detail | |
0.007 | Helicobacter Infections | NA | GAD | Detail | |
<0.001 | B-Cell Lymphomas | NA | BeFree | Detail | |
0.120 | T-Cell Lymphoma | NA | CTD_human | Detail | |
0.007 | Peripheral Vascular Diseases | NA | GAD,LHGDN | Detail | |
<0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
0.007 | gestational diabetes | NA | BeFree,GAD | Detail | |
0.002 | Ovarian Failure, Premature | NA | GAD | Detail | |
0.120 | Polycystic Kidney, Autosomal Dominant | NA | BeFree,CTD_human | Detail | |
0.003 | essential hypertension | NA | BeFree,GAD | Detail | |
<0.001 | benign neoplasm | NA | BeFree | Detail | |
<0.001 | Pseudopelade | NA | BeFree | Detail | |
0.082 | Left Ventricular Hypertrophy | NA | GAD,RGD | Detail | |
<0.001 | Thyroid Gland Follicular Adenoma | NA | BeFree | Detail | |
0.007 | Premature Birth | NA | GAD,LHGDN | Detail | |
0.003 | Myocardial Ischemia | NA | BeFree,GAD | Detail | |
0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
0.001 | esophageal carcinoma | NA | BeFree | Detail | |
0.001 | Idiopathic pulmonary hypertension | We showed that miR-27b plays a role endothelial function and NO release and eluc... | BeFree | 25795136 | Detail |
<0.001 | Malignant neoplasm of brain | NA | BeFree | Detail | |
<0.001 | Secondary malignant neoplasm of bone | On follow-up available for 17 patients (mean, 22.4 months), 16 PAX8/PPARγ-positi... | BeFree | 24798894 | Detail |
<0.001 | Disorder of endocrine ovary | NA | BeFree | Detail | |
<0.001 | proliferative diabetic retinopathy | Expression of intraocular peroxisome proliferator-activated receptor gamma in pa... | BeFree | 25468312 | Detail |
<0.001 | acute myocardial infarction | NA | BeFree | Detail | |
<0.001 | allergic asthma | NA | BeFree | Detail | |
<0.001 | Malnutrition | PPARγ links maternal malnutrition and abnormal glucose and lipid metabolism in t... | BeFree | 25608816 | Detail |
<0.001 | Right Ventricular Hypertrophy | NA | BeFree | Detail | |
<0.001 | Cicatrix, Hypertrophic | Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen ... | BeFree | 25704091 | Detail |
<0.001 | Dermatitis, Allergic Contact | NA | BeFree | Detail | |
<0.001 | Aortic Aneurysm, Abdominal | NA | BeFree | Detail | |
0.002 | Tumor Progression | NA | BeFree | Detail | |
0.002 | follicular adenoma | NA | BeFree | Detail | |
<0.001 | Anaplastic carcinoma | NA | BeFree | Detail | |
<0.001 | Undifferentiated carcinoma | NA | BeFree | Detail | |
<0.001 | fatal familial insomnia | NA | BeFree | Detail | |
0.081 | hyperandrogenism | NA | BeFree,RGD | Detail | |
<0.001 | angiomyolipoma | NA | BeFree | Detail | |
0.007 | Follicular thyroid carcinoma | Although most tumors carrying this mutation appear to be clinically indolent, at... | BeFree | 24798894 | Detail |
0.007 | Follicular thyroid carcinoma | Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Ja... | BeFree | 25708358 | Detail |
0.004 | cholangiocarcinoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Carcinoma, Large Cell | NA | BeFree | Detail | |
0.120 | gliosarcoma | NA | ORPHANET | Detail | |
<0.001 | Malignant neoplasm of salivary gland | NA | BeFree | Detail | |
0.003 | Acquired partial lipodystrophy | In the last decade, some rare mutations in human PPARγ that might be associated ... | BeFree | 25004973 | Detail |
0.003 | Acquired partial lipodystrophy | To provide a broader context for how these mutations act to generate the clinica... | BeFree | 25460295 | Detail |
<0.001 | Familial generalized lipodystrophy | Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy simil... | BeFree | 24980513 | Detail |
<0.001 | Systolic hypertension | NA | BeFree | Detail | |
0.120 | pituitary-dependent Cushing's disease | NA | CTD_human | Detail | |
<0.001 | Memory impairment | NA | BeFree | Detail | |
0.120 | Chronobiology Disorders | NA | CTD_human | Detail | |
0.002 | Anaplastic thyroid carcinoma | NA | BeFree | Detail | |
0.122 | Papillary thyroid carcinoma | In this series, PAX8/PPARγ rearrangement found in thyroid nodules had a 100% pre... | BeFree,ORPHANET | 24798894 | Detail |
0.002 | Fibrosis, Liver | Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and ... | BeFree | 25609425 | Detail |
<0.001 | Interstitial fibrosis | Morphological and haemodynamic measurements showed that the activation of PPARγ ... | BeFree | 25633415 | Detail |
<0.001 | Iron deficiency | NA | BeFree | Detail | |
0.002 | coronary stenosis | NA | GAD | Detail | |
0.018 | Malignant neoplasm of lung | NA | BeFree,GAD | Detail | |
0.200 | Acute Lung Injury | NA | CTD_human,RGD | Detail | |
0.002 | Ventricular Dysfunction, Left | NA | GAD | Detail | |
<0.001 | Sepsis | Activation of the peroxisome proliferator-activated receptor γ counteracts sepsi... | BeFree | 25559266 | Detail |
<0.001 | chronic cholangitis | NA | BeFree | Detail | |
<0.001 | Cholestasis of pregnancy | NA | BeFree | Detail | |
0.012 | Impaired glucose tolerance | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Infectious colitis | NA | BeFree | Detail | |
<0.001 | gastric adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | Taken together, these results provide new evidence for the action mechanisms of ... | BeFree | 25592041 | Detail |
<0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
<0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Solid tumour | NA | BeFree | Detail | |
0.120 | leukostasis | NA | BeFree,CTD_human | Detail | |
<0.001 | Vascular Neoplasms | NA | BeFree | Detail | |
0.001 | cervix carcinoma | The PPARγ is differentially expressed in cervical cancer cells with maximum expr... | BeFree | 24642720 | Detail |
<0.001 | Obesity, Abdominal | NA | BeFree | Detail | |
0.003 | Restenosis | NA | BeFree,GAD | Detail | |
<0.001 | Senile Plaques | NA | BeFree | Detail | |
0.120 | giant cell glioblastoma | NA | ORPHANET | Detail | |
<0.001 | Adenocarcinoma of colon | NA | BeFree | Detail | |
<0.001 | Impaired cognition | NA | BeFree | Detail | |
0.003 | Thyroid associated opthalmopathies | Moreover, dasatinib reduced PPAR-γ mRNA expression in cultured GO orbital tissue... | BeFree,GAD | 26284551 | Detail |
<0.001 | Proliferative retinopathy | NA | BeFree | Detail | |
<0.001 | Anterior myocardial infarction | NA | BeFree | Detail | |
0.005 | Complications of Diabetes Mellitus | NA | GAD | Detail | |
<0.001 | Congenital aneurysm of ascending aorta | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of liver | Taken together, these results provide new evidence for the action mechanisms of ... | BeFree | 25592041 | Detail |
0.003 | Arrhythmogenic Right Ventricular Dysplasia | NA | BeFree,GAD | Detail | |
0.003 | prediabetes syndrome | NA | BeFree,GAD | Detail | |
<0.001 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
<0.001 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
0.014 | Malignant neoplasm of prostate | We found that in vitro culture of PC-3 cells with lutein induced mild decrease i... | BeFree,GAD | 25162762 | Detail |
0.014 | Malignant neoplasm of prostate | EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulato... | BeFree,GAD | 25669987 | Detail |
0.014 | Malignant neoplasm of prostate | Further studies are needed to assess the functional role of PPAR-γ and to valida... | BeFree,GAD | 25931782 | Detail |
<0.001 | Hematopoietic Neoplasms | NA | BeFree | Detail | |
0.080 | Endotoxemia | NA | RGD | Detail | |
<0.001 | Pulmonary Cystic Fibrosis | NA | BeFree | Detail | |
0.002 | thrombophilia | NA | GAD | Detail | |
0.003 | Non-alcoholic Fatty Liver Disease | NA | BeFree | Detail | |
<0.001 | Chronic Kidney Insufficiency | NA | BeFree | Detail | |
<0.001 | Chronic small plaque psoriasis | NA | BeFree | Detail | |
0.003 | Osteoarthritis, Knee | NA | BeFree,GAD | Detail | |
0.001 | Follicular neoplasm | NA | BeFree | Detail | |
<0.001 | endometrial carcinoma | This crosstalk may facilitate the development of novel therapeutic methods targe... | BeFree | 25592200 | Detail |
<0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
0.005 | dementia | NA | BeFree,GAD | Detail | |
0.002 | body mass | NA | GAD | Detail | |
0.001 | Neurodegenerative Disorders | NA | BeFree | Detail | |
<0.001 | Hepatitis B, Chronic | NA | BeFree | Detail | |
<0.001 | Myxoid/Round Cell Liposarcoma | NA | BeFree | Detail | |
0.005 | Malignant neoplasm of esophagus | NA | BeFree,GAD | Detail | |
0.006 | Thyroid carcinoma | The posttest probability of thyroid cancer was 100% for nodules positive for BRA... | BeFree | 24811481 | Detail |
0.006 | Thyroid carcinoma | We reviewed a consecutive series of 1510 patients who had initial thyroidectomy ... | BeFree | 26258321 | Detail |
0.003 | Carotid Atherosclerosis | NA | BeFree,GAD | Detail | |
0.001 | Osteosarcoma of bone | Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ p... | BeFree | 25586304 | Detail |
<0.001 | Aqueous Humor Disorders | The PPARγ concentrations in the aqueous humor and vitreous fluid were significan... | BeFree | 25468312 | Detail |
0.015 | Carcinogenesis | Taken together, these results provide new evidence for the action mechanisms of ... | BeFree | 25592041 | Detail |
0.015 | Carcinogenesis | These findings will extend our understanding of the function of PPARγ in tumorig... | BeFree | 25944662 | Detail |
<0.001 | monocytic leukemia | NA | BeFree | Detail | |
0.010 | prostate carcinoma | We found that in vitro culture of PC-3 cells with lutein induced mild decrease i... | BeFree | 25162762 | Detail |
0.010 | prostate carcinoma | EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulato... | BeFree | 25669987 | Detail |
0.010 | prostate carcinoma | Further studies are needed to assess the functional role of PPAR-γ and to valida... | BeFree | 25931782 | Detail |
0.002 | hepatopulmonary syndrome | NA | GAD | Detail | |
0.003 | Epithelial ovarian cancer | NA | BeFree,GAD | Detail | |
0.015 | breast carcinoma | PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in... | BeFree | 24293218 | Detail |
0.015 | breast carcinoma | Collectively, our observations suggest potential applications for PTER-ITC in br... | BeFree | 25119466 | Detail |
0.015 | breast carcinoma | Lack of effects of peroxisome proliferator-activated receptor gamma genetic poly... | BeFree | 25422184 | Detail |
0.015 | breast carcinoma | We conclude that the interaction between IGFBP-3 and PPARγ is important for the ... | BeFree | 25449421 | Detail |
0.015 | breast carcinoma | Our findings suggest that omega-3 DHADA- and EPADA activation of PPARγ may assum... | BeFree | 26272430 | Detail |
0.004 | Carcinoma of lung | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of gastrointestinal tract | NA | BeFree | Detail | |
<0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
0.134 | colon carcinoma | A role for peroxisome proliferator-activated receptor gamma in resveratrol-induc... | BeFree,CLINVAR | 24975132 | Detail |
0.134 | colon carcinoma | In the last decade, some rare mutations in human PPARγ that might be associated ... | BeFree,CLINVAR | 25004973 | Detail |
0.134 | colon carcinoma | The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by ... | BeFree,CLINVAR | 25098256 | Detail |
0.002 | Carcinoma of bladder | NA | BeFree | Detail | |
0.002 | Central neuroblastoma | NA | BeFree | Detail | |
<0.001 | Atrophy, Muscular, Spinobulbar | Treatment with pioglitazone (PG), an activator of PPARγ, improved the viability ... | BeFree | 25168383 | Detail |
0.002 | Pregnancy associated hypertension | NA | GAD | Detail | |
<0.001 | Pseudomonas aeruginosa infection | NA | BeFree | Detail | |
<0.001 | Endothelial dysfunction | NA | BeFree | Detail | |
0.120 | Drug-Induced Liver Injury | NA | GWASCAT | Detail | |
<0.001 | Carcinoma, Pancreatic Ductal | NA | BeFree | Detail | |
<0.001 | Cerebral Ischemia | NA | BeFree | Detail | |
0.004 | ovarian neoplasm | NA | BeFree,LHGDN | Detail | |
0.002 | Microsatellite Instability | NA | GAD | Detail | |
0.002 | Insulin Sensitivity | NA | GAD | Detail | |
0.003 | cholecystolithiasis | NA | BeFree,GAD | Detail | |
<0.001 | Vascular inflammations | NA | BeFree | Detail | |
0.001 | Ischemic stroke | These results indicate that the C161T of PPARγ may reduce the risk of IS by modu... | BeFree | 24841086 | Detail |
0.001 | Ischemic stroke | PPARγ and IL-6 - 174G>C gene variants in Croatian patients with ischemic stroke. | BeFree | 25659766 | Detail |
0.011 | Acute coronary syndrome | NA | BeFree,GAD,LHGDN | Detail | |
0.002 | coronary restenosis | NA | GAD | Detail | |
<0.001 | Polyp of large intestine | NA | BeFree | Detail | |
<0.001 | Thyroid hyperplasia | NA | BeFree | Detail | |
0.003 | HIV-Associated Lipodystrophy Syndrome | NA | BeFree,GAD | Detail | |
0.002 | Malignant neoplasm of ovary | PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-12... | BeFree | 25944662 | Detail |
0.002 | Glucose Metabolism Disorders | NA | GAD | Detail | |
<0.001 | Chronic metabolic disorder | NA | BeFree | Detail | |
<0.001 | attention deficit hyperactivity disorder | NA | BeFree | Detail | |
0.002 | Systemic arterial pressure | NA | GAD | Detail | |
<0.001 | extraskeletal myxoid chondrosarcoma | NA | BeFree | Detail | |
<0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | Adenoma of large intestine | NA | BeFree | Detail | |
<0.001 | ACTH-secreting pituitary adenoma | NA | BeFree | Detail | |
<0.001 | Liver regeneration disorder | NA | BeFree | Detail | |
<0.001 | M5b Acute differentiated monocytic leukemia | NA | BeFree | Detail | |
<0.001 | pancreatic ductal adenocarcinoma | NA | BeFree | Detail | |
0.001 | differentiated thyroid gland carcinoma | In this series, PAX8/PPARγ rearrangement found in thyroid nodules had a 100% pre... | BeFree | 24798894 | Detail |
<0.001 | Epithelioma | NA | BeFree | Detail | |
<0.001 | Granulosa cell tumor of the ovary | NA | BeFree | Detail | |
0.002 | hearing impairment | NA | GAD | Detail | |
<0.001 | Vascular lesions | NA | BeFree | Detail | |
<0.001 | Benign melanocytic nevus | NA | BeFree | Detail | |
0.022 | Mammary Neoplasms | We conclude that the interaction between IGFBP-3 and PPARγ is important for the ... | BeFree,LHGDN | 25449421 | Detail |
<0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
<0.001 | Mammary Tumorigenesis | NA | BeFree | Detail | |
<0.001 | Cancer Cell Growth | NA | BeFree | Detail | |
<0.001 | Skin Carcinogenesis | NA | BeFree | Detail | |
0.005 | Hypertriglyceridemia result | NA | GAD | Detail | |
0.039 | colorectal cancer | The combination of resveratrol with a PPARγ agonist could be a promising pharmac... | BeFree,GAD | 24975132 | Detail |
0.039 | colorectal cancer | Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxalipla... | BeFree,GAD | 25075794 | Detail |
0.001 | Chronic Kidney Diseases | NA | BeFree | Detail | |
<0.001 | Glioblastoma multiforme | NA | BeFree | Detail | |
<0.001 | androgen independent prostate cancer | NA | BeFree | Detail | |
<0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
<0.001 | Non-Neoplastic Disorder | NA | BeFree | Detail | |
<0.001 | Familial Partial Lipodystrophy, Type 2 | NA | BeFree | Detail | |
0.080 | congenital generalized lipodystrophy type 2 | NA | MGD | Detail | |
0.120 | Carotid intimal medial thickness 1 | NA | CTD_human | Detail | |
<0.001 | Bulbo-Spinal Atrophy, X-Linked | Treatment with pioglitazone (PG), an activator of PPARγ, improved the viability ... | BeFree | 25168383 | Detail |
<0.001 | Mammographic Density | NA | BeFree | Detail | |
<0.001 | Craniometaphyseal dysplasia, autosomal dominant | NA | BeFree | Detail | |
<0.001 | Pyruvate dehydrogenase E3-binding protein deficiency | NA | BeFree | Detail | |
0.002 | Venous thromboembolism | NA | GAD | Detail | |
0.002 | Mixed hyperlipidemia (disorder) | NA | GAD | Detail | |
0.125 | liver carcinoma | MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator... | BeFree,CTD_human | 25387077 | Detail |
0.125 | liver carcinoma | Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepa... | BeFree,CTD_human | 25592041 | Detail |
0.125 | liver carcinoma | MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression... | BeFree,CTD_human | 25836616 | Detail |
<0.001 | Chronic kidney disease stage 5 | Sequence variants of peroxisome proliferator-activated receptor-gamma gene and t... | BeFree | 25784779 | Detail |
<0.001 | Childhood myelodysplastic syndrome | NA | BeFree | Detail | |
<0.001 | Idiopathic Interstitial Pneumonias | NA | BeFree | Detail | |
<0.001 | Pediatric Obesity | NA | BeFree | Detail | |
<0.001 | Allergic rhinitis (disorder) | NA | BeFree | Detail | |
0.200 | Acute kidney injury | NA | CTD_human,RGD | Detail | |
<0.001 | Hypoadiponectinemia | NA | BeFree | Detail | |
0.001 | Steatohepatitis | NA | BeFree | Detail | |
<0.001 | Promyelocytic leukemia | NA | BeFree | Detail | |
0.017 | Weight Loss Adverse Event | NA | GAD | Detail | |
0.014 | Weight Gain Adverse Event | NA | GAD | Detail | |
0.002 | Infection of amniotic sac and membranes, unspecified, unspecified trimester, not applicable or unspecified | NA | GAD | Detail | |
0.005 | Chronic ulcerative colitis | NA | GAD | Detail | |
0.120 | Thyroid cancer, follicular | NA | CTD_human | Detail | |
<0.001 | Gestational trophoblastic disease | NA | BeFree | Detail | |
<0.001 | Plaque, Amyloid | NA | BeFree | Detail | |
<0.001 | Scarring alopecia | NA | BeFree | Detail | |
0.001 | Pulmonary arterial hypertension | We showed that miR-27b plays a role endothelial function and NO release and eluc... | BeFree | 25795136 | Detail |
0.080 | Idiopathic pulmonary arterial hypertension | NA | MGD | Detail | |
0.001 | Ischemic Cerebrovascular Accident | These results indicate that the C161T of PPARγ may reduce the risk of IS by modu... | BeFree | 24841086 | Detail |
0.001 | Ischemic Cerebrovascular Accident | PPARγ and IL-6 - 174G>C gene variants in Croatian patients with ischemic stroke. | BeFree | 25659766 | Detail |
0.002 | granulomatosis with polyangiitis | NA | GAD | Detail | |
<0.001 | Triple Negative Breast Neoplasms | NA | BeFree | Detail | |
<0.001 | Neutrophilia (disorder) | NA | BeFree | Detail | |
<0.001 | Melanocytic nevus of skin | NA | BeFree | Detail | |
0.003 | Infection | NA | LHGDN | Detail | |
<0.001 | Insulin resistance syndrome | NA | BeFree | Detail | |
0.001 | Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia | We showed that miR-27b plays a role endothelial function and NO release and eluc... | BeFree | 25795136 | Detail |
0.002 | Hearing Loss | NA | GAD | Detail | |
<0.001 | Congenital Abnormality | NA | BeFree | Detail | |
<0.001 | acanthosis nigricans | NA | BeFree | Detail | |
0.001 | acromegaly | NA | BeFree | Detail | |
0.138 | adenocarcinoma | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
0.013 | adenoma | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Tumors of Adrenal Cortex | NA | BeFree | Detail | |
0.002 | Albuminuria | NA | GAD | Detail | |
0.002 | Alcoholic Intoxication, Chronic | NA | GAD | Detail | |
0.004 | amyotrophic lateral sclerosis | Taken together, our data provide evidence that modulating PPARγ activity, althou... | BeFree,GAD | 25432537 | Detail |
<0.001 | Anaplasia | NA | BeFree | Detail | |
<0.001 | aplastic anemia | NA | BeFree | Detail | |
0.002 | Angina Pectoris, Variant | NA | GAD | Detail | |
<0.001 | aortic aneurysm | NA | BeFree | Detail | |
<0.001 | arthritis | NA | BeFree | Detail | |
0.003 | Arthritis, Psoriatic | NA | BeFree,GAD | Detail | |
0.006 | rheumatoid arthritis | NA | BeFree,GAD | Detail | |
0.008 | asthma | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Ataxia | NA | BeFree | Detail | |
<0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
0.120 | Barrett esophagus | NA | CTD_human | Detail | |
0.002 | Biliary Tract Neoplasm | NA | GAD | Detail | |
0.007 | Malignant neoplasm of urinary bladder | NA | BeFree,GAD | Detail | |
0.088 | Bladder Neoplasm | NA | BeFree,LHGDN,RGD | Detail | |
<0.001 | borderline personality disorder | NA | BeFree | Detail | |
<0.001 | Brain Neoplasms | NA | BeFree | Detail | |
0.023 | Malignant neoplasm of breast | PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in... | BeFree,GAD | 24293218 | Detail |
0.023 | Malignant neoplasm of breast | Collectively, our observations suggest potential applications for PTER-ITC in br... | BeFree,GAD | 25119466 | Detail |
0.023 | Malignant neoplasm of breast | Lack of effects of peroxisome proliferator-activated receptor gamma genetic poly... | BeFree,GAD | 25422184 | Detail |
0.023 | Malignant neoplasm of breast | We conclude that the interaction between IGFBP-3 and PPARγ is important for the ... | BeFree,GAD | 25449421 | Detail |
0.023 | Malignant neoplasm of breast | Our findings suggest that omega-3 DHADA- and EPADA activation of PPARγ may assum... | BeFree,GAD | 26272430 | Detail |
<0.001 | bronchopulmonary dysplasia | NA | BeFree | Detail | |
0.002 | calcinosis | NA | GAD | Detail | |
0.013 | Malignant tumor of colon | A role for peroxisome proliferator-activated receptor gamma in resveratrol-induc... | BeFree | 24975132 | Detail |
0.013 | Malignant tumor of colon | In the last decade, some rare mutations in human PPARγ that might be associated ... | BeFree | 25004973 | Detail |
0.013 | Malignant tumor of colon | The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by ... | BeFree | 25098256 | Detail |
<0.001 | Adenocarcinoma of prostate | Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Aden... | BeFree | 25931782 | Detail |
0.001 | Rectal Carcinoma | NA | BeFree | Detail | |
0.004 | Malignant neoplasm of thyroid | The posttest probability of thyroid cancer was 100% for nodules positive for BRA... | BeFree | 24811481 | Detail |
0.004 | Malignant neoplasm of thyroid | We reviewed a consecutive series of 1510 patients who had initial thyroidectomy ... | BeFree | 26258321 | Detail |
0.007 | Non-small cell lung carcinoma | NA | BeFree,LHGDN | Detail | |
0.001 | Carcinoma, Papillary | NA | BeFree | Detail | |
0.003 | renal cell carcinoma | NA | BeFree,GAD | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ genetic variation has been associated with metabolic and cardiovascular diseases. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The PPARγ is differentially expressed in cervical cancer cells with maximum expression in ME180 cell... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Altogether these data demonstrate that PAK1 overexpression and activation in inflammation and coliti... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach fo... | DisGeNET | Detail |
Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPAR... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The gene polymorphisms of UCP1 but not PPAR γ and TCF7L2 are associated with diabetic retinopathy in... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have a role of antineoplastic in vario... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The sEng, sFlt-1, and interleukin-6 were up-regulated, whereas the VEGF and PlGF were down-regulated... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1... | DisGeNET | Detail |
Modulation of peroxisome proliferator-activated receptor gamma (PPAR γ) by conjugated fatty acid in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Nitroalkene derivatives of oleic acid (OA-NO2) serve as high-affinity ligand for PPAR-γ, which regul... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The phenotype and presence of two mutations suggests that biallelic mutations at PPARG cause a CGL s... | DisGeNET | Detail |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Similarly E2F transcription factors and PPARγ function in both progenitors and medulloblastoma to op... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-activated transcription factor h... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we explored the distribution and role of the mitochondrial antioxidants peroxiredoxin... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association of PPARγ gene polymorphisms with osteoarthritis in a southeast Chinese population. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway. | DisGeNET | Detail |
PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a key regulator of mitochondri... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Further mechanistic study is needed to elucidate the role of PPAR-γ among ESRD patients. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have genotyped three single nucleotide polymorphisms associated with type 2 diabetes in a large t... | DisGeNET | Detail |
In contrast, the well-documented associations of peroxisome proliferator-activated receptor gamma P1... | DisGeNET | Detail |
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis s... | DisGeNET | Detail |
A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activate... | DisGeNET | Detail |
Activation of the peroxisome proliferator-activated receptor γ counteracts sepsis-induced T cell cyt... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ was not statistically significantly associated with stroke. | DisGeNET | Detail |
NA | DisGeNET | Detail |
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular th... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We showed that miR-27b plays a role endothelial function and NO release and elucidated a potential m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
On follow-up available for 17 patients (mean, 22.4 months), 16 PAX8/PPARγ-positive cancers showed no... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Expression of intraocular peroxisome proliferator-activated receptor gamma in patients with prolifer... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ links maternal malnutrition and abnormal glucose and lipid metabolism in the offspring of mice... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human h... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Although most tumors carrying this mutation appear to be clinically indolent, at least on short-term... | DisGeNET | Detail |
Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In the last decade, some rare mutations in human PPARγ that might be associated with partial lipodys... | DisGeNET | Detail |
To provide a broader context for how these mutations act to generate the clinical features of partia... | DisGeNET | Detail |
Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinel... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this series, PAX8/PPARγ rearrangement found in thyroid nodules had a 100% predictive value for di... | DisGeNET | Detail |
Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by ep... | DisGeNET | Detail |
Morphological and haemodynamic measurements showed that the activation of PPARγ improved the impaire... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Activation of the peroxisome proliferator-activated receptor γ counteracts sepsis-induced T cell cyt... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, these results provide new evidence for the action mechanisms of PPARγ in carcinogene... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The PPARγ is differentially expressed in cervical cancer cells with maximum expression in ME180 cell... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, dasatinib reduced PPAR-γ mRNA expression in cultured GO orbital tissue. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, these results provide new evidence for the action mechanisms of PPARγ in carcinogene... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that in vitro culture of PC-3 cells with lutein induced mild decrease in proliferation that... | DisGeNET | Detail |
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory ef... | DisGeNET | Detail |
Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic i... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This crosstalk may facilitate the development of novel therapeutic methods targeting PPARγ in endome... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% fo... | DisGeNET | Detail |
We reviewed a consecutive series of 1510 patients who had initial thyroidectomy for TC with routine ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway. | DisGeNET | Detail |
The PPARγ concentrations in the aqueous humor and vitreous fluid were significantly higher in PDR pa... | DisGeNET | Detail |
Taken together, these results provide new evidence for the action mechanisms of PPARγ in carcinogene... | DisGeNET | Detail |
These findings will extend our understanding of the function of PPARγ in tumorigenesis and miR-125b ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that in vitro culture of PC-3 cells with lutein induced mild decrease in proliferation that... | DisGeNET | Detail |
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory ef... | DisGeNET | Detail |
Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic i... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells... | DisGeNET | Detail |
Collectively, our observations suggest potential applications for PTER-ITC in breast cancer preventi... | DisGeNET | Detail |
Lack of effects of peroxisome proliferator-activated receptor gamma genetic polymorphisms on breast ... | DisGeNET | Detail |
We conclude that the interaction between IGFBP-3 and PPARγ is important for the growth-inhibitory ef... | DisGeNET | Detail |
Our findings suggest that omega-3 DHADA- and EPADA activation of PPARγ may assume biological relevan... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell... | DisGeNET | Detail |
In the last decade, some rare mutations in human PPARγ that might be associated with partial lipodys... | DisGeNET | Detail |
The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by down-regulating PPAR... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Treatment with pioglitazone (PG), an activator of PPARγ, improved the viability of the cellular mode... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results indicate that the C161T of PPARγ may reduce the risk of IS by modulation of adipose me... | DisGeNET | Detail |
PPARγ and IL-6 - 174G>C gene variants in Croatian patients with ischemic stroke. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this series, PAX8/PPARγ rearrangement found in thyroid nodules had a 100% predictive value for di... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We conclude that the interaction between IGFBP-3 and PPARγ is important for the growth-inhibitory ef... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach fo... | DisGeNET | Detail |
Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPAR... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Treatment with pioglitazone (PG), an activator of PPARγ, improved the viability of the cellular mode... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor ... | DisGeNET | Detail |
Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via... | DisGeNET | Detail |
MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene ... | DisGeNET | Detail |
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We showed that miR-27b plays a role endothelial function and NO release and elucidated a potential m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results indicate that the C161T of PPARγ may reduce the risk of IS by modulation of adipose me... | DisGeNET | Detail |
PPARγ and IL-6 - 174G>C gene variants in Croatian patients with ischemic stroke. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We showed that miR-27b plays a role endothelial function and NO release and elucidated a potential m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, our data provide evidence that modulating PPARγ activity, although not effective at ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells... | DisGeNET | Detail |
Collectively, our observations suggest potential applications for PTER-ITC in breast cancer preventi... | DisGeNET | Detail |
Lack of effects of peroxisome proliferator-activated receptor gamma genetic polymorphisms on breast ... | DisGeNET | Detail |
We conclude that the interaction between IGFBP-3 and PPARγ is important for the growth-inhibitory ef... | DisGeNET | Detail |
Our findings suggest that omega-3 DHADA- and EPADA activation of PPARγ may assume biological relevan... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell... | DisGeNET | Detail |
In the last decade, some rare mutations in human PPARγ that might be associated with partial lipodys... | DisGeNET | Detail |
The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by down-regulating PPAR... | DisGeNET | Detail |
Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% fo... | DisGeNET | Detail |
We reviewed a consecutive series of 1510 patients who had initial thyroidectomy for TC with routine ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386597997 dbSNP
- Genome
- hg38
- Position
- chr3:12,287,368-12,434,356
- Variant Type
- snv
Genome browser